Document Detail

Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's disease.
MedLine Citation:
PMID:  14687146     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Infliximab is an effective therapy for fistulizing Crohn's disease of the perineum. We sought to determine whether the clinical improvement after infliximab is associated with radiological closure of fistula tracts. METHODS: Clinical responses and radiological imaging studies by transperineal ultrasound were evaluated in 35 patients with Crohn's disease perianal fistulas after treatment with infliximab 5 mg/kg up to 48 wk. Paired comparison of baseline and follow-up imaging studies at 8 wk and at 56 wk or discontinuation were assessed by an imaging score of perianal fistula severity, based on the Parks criteria. Complete clinical fistula closure and radiological healing were primary outcome measures. RESULTS: At 8 wk, after two infusions of infliximab at 0 and 2 wk, clinical fistula closure occurred in 49% of patients. The radiological score at 8 wk was higher for patients with clinical fistula closure than for patients with no clinical improvement (p= 0.023) and two patients showed complete radiological healing. At 56 wk, clinical fistula closure occurred in 46% patients. Clinical fistula scores correlated with radiological scores (R2= 0.52; p < 0.001) but were not associated with fistula complexity, number of fistulas, or number of collections at baseline imaging. The proportion of patients with marked radiological improvement increased from 14% at 8 wk to 43% at 56 wks (p= 0.015) and complete radiological healing occurred in 4 (11%) patients. CONCLUSIONS: For perianal fistulizing Crohn's disease, repeat dose infliximab improves clinical and radiological outcomes, although complete radiological healing occurs in a minority of patients.
Imran Rasul; Stephanie R Wilson; Helen MacRae; Sue Irwin; Gordon R Greenberg
Related Documents :
21110496 - Treatment of partial-thickness scalds by skin xenografts--a retrospective study of 109 ...
17845686 - Collagenous colitis: oral low-dose methotrexate for patients with difficult symptoms: l...
24336016 - Benefits from new adp-antagonists as compared to clopidogrel in patients with stable an...
23287566 - Arm composite autogenous vascular access using the great saphenous vein and the femoral...
24979116 - Drug-eluting stents vs. bare metal stents in patients with cardiogenic shock: a compari...
23782896 - Diasurg 2 trial - surgical vs. medical treatment of insulin-dependent type 2 diabetes m...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  99     ISSN:  0002-9270     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  2004 Jan 
Date Detail:
Created Date:  2003-12-22     Completed Date:  2004-02-05     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  82-8     Citation Subset:  IM    
Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University of Toronto, Toronto, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Crohn Disease / complications,  drug therapy*,  ultrasonography
Rectal Fistula / drug therapy*,  etiology,  ultrasonography
Rectovaginal Fistula / drug therapy*,  etiology,  ultrasonography
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/infliximab
Comment In:
Am J Gastroenterol. 2004 Jan;99(1):89-90   [PMID:  14687147 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol r...
Next Document:  Remission in patients with Crohn's disease is associated with improvement in employment and quality ...